Press release

Amniotics AB presents new preclinical data at the International Society for Cell & Gene Therapy meeting in San Francisco

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that COO Jan Talts will present two posters at the 30th Annual meeting of the International Society for Cell & Gene Therapy, taking place in San Francisco in the US 4-7th of May.

The titles of the posters are “Lung tissue type selected amniotic fluid derived mesenchymal stem cells for treatment of bleomycin induced pulmonary fibrosis in a rat model” and “Extracellular Vesicles (EVs) derived from amniotic fluid mesenchymal stem cells selected by skin tissue type markers reduce inflammation”.

This new data provides insights on Amniotics cell sorting processes and validation of the selection methods of stem cells that are specific for the lung and for skin respectively using a bioinformatics approach followed by verification of selected cell surface targets by flow cytometry.

In addition, the first poster shows that lung specific stem cells were effective in reducing lung fibrosis in a bleomycin-induced pulmonary fibrosis model. No adverse reactions were observed, and the stem cells were no longer detected in the rats after day 24, supporting that the stem cells were cleared after exerting their effect. The second poster showed that extracellular vesicles derived from skin specific stem cells in high purity and concentration, significantly decreased inflammation in skin, in an in vitro cell activation model.

“We are excited to share our validated stem cell selection process, which has proven effective in extracting stem cells that are highly specific to the organs we are aiming to treat. Moreover, the data on our lung specific stem cells gives us strong support in their potential to treat patients suffering from lung diseases with fibrotic components like idiopathic pulmonary fibrosis. The data on extracellular vesicles, which are also derived from amniotic fluid stem cells, is quite interesting as EVs open a new and potentially faster route to the patients “, says Jan Talts, COO at Amniotics.

The posters are presented by Amniotic’s COO Jan Talts on Wednesday May 4, btw 18:30 - 20:00 (Pacific time)/ Thursday May 5, 03.30-05.00 (Central European).

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has it´s headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at www.amniotics.com.

IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Amniotics. Invitation to the persons concerned to subscribe for units consisting of shares and warrants in Amniotics has only taken place through the prospectus that Amniotics published on June 14, 2021.